IM Cannabis

growth-negative

IM Cannabis Corp. has experienced a 24% decline in stock price, affecting insiders who acquired CA$1.13 million worth of shares at an average price of CA$2.07 over the past year. Despite the decline, insiders, including CEO Oren Shuster, have shown confidence by purchasing shares at higher prices than the current market value. Insiders own about US$3.0 million worth of shares, representing 41% of the company, indicating strong insider ownership. The article suggests that insiders are bullish about the companys future, although the recent stock performance has been negative. The company is involved in the healthcare sector, with a focus on AI technology.

growth-negative

IM Cannabis Corp., a leading international medical cannabis company with operations in Israel and Germany, announced that its Chief Financial Officer, Uri Birenberg, will be stepping down for personal reasons. He will continue in his role until January 5, 2026, or an earlier date as determined by the company, to assist in a structured transition process until a successor is appointed. The company operates in Israel and Germany, providing premium cannabis products to medical patients. The departure of the CFO is seen as a significant management change, potentially impacting the companys operations and strategic direction.

growth-negative

IM Cannabis Corp., a leading international medical cannabis company operating in Israel and Germany, announced that its Chief Financial Officer, Uri Birenberg, will step down for personal reasons. Birenberg will continue in his role until January 5, 2026, or an earlier date as determined by the company, assisting in a structured transition process. The announcement highlights the companys commitment to finding a successor and maintaining its operations in the medical cannabis markets of Israel and Germany. The company leverages a transnational ecosystem and a data-driven approach to provide premium cannabis products. The departure of a key executive is a significant change, potentially impacting the companys strategic direction and operations.

growth-positive

IM Cannabis Corp., a leading medical cannabis company, announced a non-binding indicative term sheet to acquire a 60% equity interest in a quantum computing bio data company for up to $54 million. This acquisition aims to enhance IMCs long-term growth opportunities by integrating advanced quantum computing technologies into their operations. The transaction is subject to due diligence, negotiation, and regulatory approvals. IMC is focused on expanding its business activities to create further shareholder value and strengthen its position in the medical cannabis markets of Israel and Germany.

growth-positive

IM Cannabis Corp. (IMC), a leading medical cannabis company operating in Israel and Germany, has announced a non-binding indicative term sheet to acquire a 60% equity interest in a pioneering quantum computing bio data company. The acquisition is valued at up to $54 million and aims to enhance IMCs long-term growth opportunities and shareholder value. The transaction is subject to due diligence, negotiation, and regulatory approvals. IMC is committed to expanding its business activities and leveraging its transnational ecosystem to become a global high-quality cannabis player. The company operates in Israel and Germany, providing premium cannabis products to medical patients.

growth-positive

IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, announced changes to its Board of Directors effective September 15, 2025. Shmulik Arbel and Brian Schinderle have resigned, and Asaf Yitzhaik and Eli Zamir have been appointed to fill their positions. Additionally, Oz Adler has been appointed as the new Chairman of the Board, replacing Oren Shuster, who remains CEO. The company is exploring new business activities to enhance long-term growth and shareholder value.

growth-positive

IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, announced changes to its Board of Directors effective September 15, 2025. Shmulik Arbel and Brian Schinderle have resigned, and Asaf Yitzhaik and Eli Zamir have been appointed to fill the vacancies. The company also appointed Oz Adler as the new Chairman of the Board. These changes are part of IMCs strategic review to explore additional business activities aimed at enhancing long-term growth opportunities and shareholder value. The company continues to focus on sustainable growth in its key markets, leveraging a data-driven approach and a global supply chain.

growth-positive

IM Cannabis Corp., a leading medical cannabis company with operations in Israel and Germany, announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) as of September 4, 2025. This compliance ensures that the companys common stock will continue to be listed and traded on the Nasdaq Capital Market. IM Cannabis provides premium cannabis products to medical patients in Israel and Germany, leveraging a transnational ecosystem and a data-driven approach. The company operates through subsidiaries in Israel and Adjupharm GmbH in Germany, distributing cannabis to medical patients and pharmacies.

growth-negative

IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, announced changes to its November 2024 Warrants, reducing the exercise price and extending the expiration date. Additionally, the company filed a resale registration statement on Form F-3 with the SEC, covering nearly 5 million common shares, including shares issuable upon exercise of various warrants. The registration statement has not yet become effective, and the company will not receive proceeds from the sale of these securities by selling shareholders. The adjustments to the warrants and the filing of the registration statement indicate a strategic move to manage its financial instruments and shareholder interests.

growth-positive

IM Cannabis Corp. reported its financial results for Q2 2025, highlighting a 14% decrease in revenue compared to Q2 2024, primarily due to challenges in Israel and Germany. Despite this, the company achieved a 306% increase in gross profit and a 371% increase in gross margin. The company also reported an EBITDA profit of $0.1 million, a significant improvement from the $2.3 million loss in Q2 2024. The management attributed these results to disciplined cost management and operational efficiency. The company remains optimistic about recovering the revenue impact in the coming quarters and is focused on sustainable growth.

growth-positive

IM Cannabis Corp., a leading medical cannabis company, will report its operational and financial results for the second quarter of 2025 on August 12, 2025. The company operates in Israel and Germany, focusing on sustainable and profitable growth in these high-value markets. IM Cannabis leverages a transnational ecosystem with a data-driven approach and a globally sourced product supply chain. The company is committed to responsible growth and compliance with strict regulatory environments. In Israel, it operates through subsidiaries that import and distribute cannabis to medical patients, while in Germany, it distributes cannabis to pharmacies through Adjupharm GmbH.

growth-positive

IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, announced the closing of a private placement offering on July 30, 2025. The company issued 2,050,000 units at a price of C$2.7427 per unit, raising gross proceeds of approximately US$4.1 million. Each unit consists of one common share or a pre-funded common share purchase warrant, and one common share purchase warrant. Pure Equity Ltd. acted as a consultant for the offering. The securities are subject to a hold period under Canadian securities laws, and the company plans to file a resale registration statement with the U.S. SEC.

growth-positive

IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, announced the filing and effectiveness of a shelf registration statement on Form F-3 with the SEC. This registration allows the company to offer and sell up to $50 million of its common shares, warrants, units, or a combination thereof, subject to market conditions and capital needs. The company emphasizes its commitment to responsible growth and compliance with regulatory environments, aiming to strengthen its position in the medical cannabis markets of Israel and Germany. The registration does not obligate the company to sell any specific amount of securities, and any offerings will depend on market conditions.

growth-positive

IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, has appointed Mr. Oz Adler to its board of directors as part of a loan agreement with L.I.A. Pure Capital Ltd. The agreement, effective July 6, 2025, provides IM Cannabis with a USD 1 million loan, with the potential for an additional USD 1 million. The loan is secured by a pledge over 100% of the shares of IMC Holdings Ltd., a subsidiary of the company. The company aims to raise at least USD 3 million through an underwritten offering, with Aegis Capital Corp. as the underwriter.

growth-negative

IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, received a deficiency letter from Nasdaq on April 9, 2025, for not meeting the minimum stockholders equity requirement of $2.5 million. The company submitted a compliance plan on May 23, 2025, and was granted an extension until October 6, 2025, to meet the requirement. Failure to comply by the deadline may result in delisting, although the company can appeal the decision. The noncompliance does not immediately affect the trading of the companys shares on Nasdaq. IM Cannabis is committed to regaining compliance and maintaining its Nasdaq listing.

growth-positive

IM Cannabis Corp. (IMC) has announced its decision to voluntarily delist its common shares from the Canadian Securities Exchange (CSE) while maintaining its listing on NASDAQ. The company believes that the trading volume on the CSE does not justify the associated costs and administrative burdens of a dual listing. By focusing on NASDAQ, IMC aims to create a central marketplace for its shares, which is expected to enhance long-term liquidity and shareholder value. The final trading day on the CSE is anticipated to be June 2, 2025, pending approval. IMC operates in Israel and Germany, providing premium cannabis products to medical patients.

growth-positive

IM Cannabis Corp (NASDAQ:IMCC) reported a significant financial turnaround in Q1 2025, achieving a net profit of 0.2 million CAD compared to a loss of 6 million CAD in Q1 2024. The company saw an 87% improvement in gross margin and a 569% increase in revenue from the German market, indicating successful market expansion. Operating expenses decreased by 56%, contributing to a positive adjusted EBITDA of 0.6 million CAD. However, revenue from the Israeli market declined by 56%, partly due to the cancellation of the organin bill. Despite profitability, IM Cannabis Corp faces challenges in securing additional capital and balancing operations across markets. The company is also working on regulatory processes to convert long-term loans to equity investments.

growth-positive

IM Cannabis Corp. (IMC) reported significant financial improvements for Q1 2025, achieving net profitability and an 87% improvement in gross margin compared to the previous year. The company saw a 94% increase in gross profit and a 4% increase in revenue year-over-year. Operating expenses decreased by 50%, contributing to a 129% increase in Non-IFRS Adjusted EBITDA profit. IMC plans to complete a non-brokered private placement of secured convertible debentures for up to C$2.5 million. These financial results highlight the effectiveness of IMCs strategic and operational initiatives, positioning the company for sustained growth.

growth-positive

IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, has announced the filing of a management information circular in preparation for its upcoming annual general and special meeting of shareholders. The meeting is scheduled for May 23, 2025, and will be held in Toronto, Ontario. Shareholders as of the record date, March 31, 2025, are entitled to vote at the meeting. The company is utilizing a notice-and-access mechanism to deliver meeting materials electronically to non-registered shareholders, while registered shareholders will receive paper copies. This approach aims to streamline the process and ensure efficient communication with shareholders.

growth-positive

IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, is set to report its operational and financial results for the first quarter of 2025 on May 15, 2025. The company will host a Zoom web conference to discuss these results and engage with the investment community. IM Cannabis focuses on sustainable and profitable growth in its key markets, leveraging a data-driven approach and a globally sourced supply chain. The company operates through partnerships with Focus Medical Herbs Ltd. in Israel and Adjupharm GmbH in Germany, distributing cannabis to medical patients. The announcement is expected to have a growth-positive impact on the company.

growth-positive

IM Cannabis Corp. announced its financial results for Q4 and the year ending December 31, 2024, highlighting a 25% increase in Q4 revenue compared to Q4 2023 and an 11% annual increase. The company achieved a $0.5M adjusted EBITDA profit in Q4 2024, a significant improvement from the $4.3M loss in Q4 2023. Operating expenses decreased by 42% in Q4 2024 compared to Q4 2023, contributing to the companys improved financial performance. IMCs revenue in Germany increased by 183% in 2024, reaching $15.5M. The company anticipates further improvements in 2025, with Q1 expected to be the best quarter in sales in Germany.

growth-positive

IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, is set to report its operational and financial results for the fourth quarter and full year 2024 on March 31, 2025. The company will host a Zoom web conference to discuss the results and engage with the investment community. IM Cannabis focuses on sustainable and profitable growth in its key markets, leveraging a data-driven approach and a globally sourced supply chain. The company operates through partnerships in Israel and Germany, distributing cannabis to medical patients and pharmacies.

growth-neutral

IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, has announced a change in its auditor. The company has transitioned from Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, to Fahn Kanne & Co. Grant Thornton Israel, effective January 16, 2025. This change was made at the companys request and was approved by the board of directors following the audit committees recommendation. The change of auditor notice has been filed on SEDAR+ as required. IM Cannabis Corp. continues to focus on providing premium cannabis products to medical patients in its key markets, leveraging a data-driven approach and a global supply chain.

growth-positive

IM Cannabis Corp. (IMC), a multi-country operator in the medical cannabis sector, has received approval to list its common shares on the NASDAQ Capital Market under the symbol IMCC. The shares are expected to begin trading on March 1, 2021. This move is part of IMCs international growth strategy and aims to enhance shareholder value through increased liquidity and access to the largest capital market. The listing is subject to regulatory requirements, including the effectiveness of the companys Form 40-F Registration Statement with the SEC. IMC operates in Israel and Germany, with a strong presence in the European medical cannabis market through its subsidiary, Adjupharm GmbH.